PL372941A1 - Sposoby terapeutyczne i zastosowanie sapogenin i ich pochodnych - Google Patents

Sposoby terapeutyczne i zastosowanie sapogenin i ich pochodnych

Info

Publication number: PL372941A1
Authority: PL; Poland
Prior art keywords: derivatives; sapogenins; cognitive; methods; theraputic
Prior art date: 2002-03-27

Application number

PL03372941A

Other languages

English (en)

Other versions

PL213697B1 (pl

Inventor

Daryl Rees

Phil Gunning

Antonia Orsi

Zongqin Xia

Yaer Hu

Original Assignee

Phytopharm Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-27

Filing date

2003-03-27

Publication date

2005-08-08

2002-03-27 Priority claimed from ARP020101170A external-priority patent/AR033079A1/es

2003-03-27 Application filed by Phytopharm Plc filed Critical Phytopharm Plc

2005-08-08 Publication of PL372941A1 publication Critical patent/PL372941A1/pl

2013-04-30 Publication of PL213697B1 publication Critical patent/PL213697B1/pl

Links

INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title 1
230000001149 cognitive effect Effects 0.000 abstract 3
230000004770 neurodegeneration Effects 0.000 abstract 2
230000002232 neuromuscular Effects 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
230000007850 degeneration Effects 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000003637 steroidlike Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Catalysts (AREA)

PL372941A 2002-03-27 2003-03-27 Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych PL213697B1 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ARP020101170A AR033079A1 (es)	2001-03-28	2002-03-27	Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso
US36817802P	2002-03-28	2002-03-28
PCT/GB2002/001578 WO2002079221A2 (en)	2001-03-28	2002-03-28	Sapogenin derivatives, their synthesis and use

Publications (2)

Publication Number	Publication Date
PL372941A1 true PL372941A1 (pl)	2005-08-08
PL213697B1 PL213697B1 (pl)	2013-04-30

Family

ID=30001210

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL372941A PL213697B1 (pl)	2002-03-27	2003-03-27	Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych

Country Status (10)

Country	Link
KR (1)	KR20100093621A (pl)
CN (1)	CN1642558B (pl)
AT (1)	ATE424211T1 (pl)
IL (1)	IL164161A0 (pl)
NZ (2)	NZ547897A (pl)
PE (1)	PE20040306A1 (pl)
PL (1)	PL213697B1 (pl)
RU (1)	RU2332999C2 (pl)
TW (1)	TWI329016B (pl)
WO (1)	WO2003082893A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6861788B2 (en) *	2003-06-03	2005-03-01	Motorola, Inc.	Switchable display/mirror method and apparatus
FR2868700B1 (fr) *	2004-04-09	2008-09-26	Michel Coisy	Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
GB0409567D0 (en)	2004-04-28	2004-06-02	Phytopharm Plc	Chemical compounds
GB0424528D0 (en)	2004-11-05	2004-12-08	Phytopharm Plc	Chemical compounds
TR201708352T4 (tr)	2005-10-28	2018-11-21	Univ Industry Cooperation Group Kyung Hee Univ	Dioscoreaceae familyasına ait özüt ve periferik nöropatinin önlenmesi veya tedavi edilmesi için bunu içeren bileşim.
AU2010207597A1 (en)	2009-01-24	2011-08-18	Phytopharm Plc	Treatment of neurotrophic factor mediated disorders
RU2402325C1 (ru) *	2009-02-02	2010-10-27	Государственное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию"	Способ лечения нейрососудистых осложнений сахарного диабета
BR112013001422A2 (pt) *	2010-07-20	2019-09-24	Phytopharm Plc	metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson
HUE062616T2 (hu)	2011-09-08	2023-11-28	Sage Therapeutics Inc	Neuroaktív szteroidok, készítmények és alkalmazásaik
CU20110244A7 (es) *	2011-12-27	2013-08-29	Ct De Investigación Y Desarrollo De Medicamentos Cidem	Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
US11319338B2 (en)	2012-04-03	2022-05-03	Goldporp Pharma Limited	Timosaponin compounds
FI3932932T3 (fi)	2013-03-13	2025-10-15	Sage Therapeutics Inc	Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
CN103232520A (zh) *	2013-05-13	2013-08-07	中国药科大学	一种螺甾类化合物、其制备方法及医药用途
JP6628745B2 (ja)	2014-06-18	2020-01-15	セージセラピューティクス，インコーポレイテッド	オキシステロールおよびその使用方法
WO2017007832A1 (en)	2015-07-06	2017-01-12	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
PT3319611T (pt)	2015-07-06	2021-04-22	Sage Therapeutics Inc	Oxisteróis e métodos de utilização dos mesmos
DK3812392T3 (da)	2015-07-06	2025-07-21	Sage Therapeutics Inc	Oxysteroler og fremgangsmåder til anvendelse deraf
ES2921010T3 (es)	2016-04-01	2022-08-16	Sage Therapeutics Inc	Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en)	2016-05-06	2017-11-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
WO2018009867A1 (en)	2016-07-07	2018-01-11	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
MA46351A (fr)	2016-09-30	2021-06-02	Sage Therapeutics Inc	Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
DK3529257T3 (da)	2016-10-18	2023-08-07	Sage Therapeutics Inc	Oxysteroler og fremgangsmåder til anvendelse deraf
KR102521573B1 (ko)	2016-10-18	2023-04-14	세이지 테라퓨틱스, 인크.	옥시스테롤 및 그의 사용 방법
CN108264535A (zh)	2016-12-30	2018-07-10	中国科学院上海药物研究所	一种抗抑郁化合物及其制备方法和应用
RU2635485C1 (ru) *	2017-03-21	2017-11-13	Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации	Способ лечения атрофии зрительного нерва после черепно-мозговой травмы
CN109988218B (zh) *	2017-12-29	2022-11-25	中国科学院上海药物研究所	一种菝葜皂苷元衍生物及其制备方法和应用
EP3572085A1 (en) *	2018-05-25	2019-11-27	Neuro-Sys	Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN112457362B (zh) *	2019-09-06	2023-09-19	上海青东生物科技有限公司	一种卤代四环三萜衍生物及其制备与应用
WO2023205801A2 (en)	2022-04-22	2023-10-26	Asteroid Therapeutics	Steroidal compositions and methods of treating lipogenic cancers
CN118994294A (zh) *	2024-08-08	2024-11-22	吉林农业大学	薤白中新甾体皂苷的分离鉴定及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3416112A1 (de) *	1984-04-30	1985-10-31	Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen	Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren
US4680289A (en) *	1985-06-05	1987-07-14	Progenics, Inc.	Treatment of obesity and diabetes using sapogenins
JPH05246866A (ja) *	1992-03-06	1993-09-24	Ruibosuteii Japan:Kk	脳代謝促進・脳機能改善剤
DE4303214A1 (de) *	1993-02-04	1994-08-11	Wolfgang Marks	Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
TW479061B (en) *	1993-12-24	2002-03-11	Mitsubishi Chem Corp	Sialic acid derivatives
JPH092956A (ja) *	1995-06-22	1997-01-07	Mitsubishi Chem Corp	神経障害の治療、予防薬
JPH092957A (ja) *	1995-06-22	1997-01-07	Mitsubishi Chem Corp	末梢性神経障害の治療、予防薬
US6046185A (en) *	1996-07-11	2000-04-04	Inflazyme Pharmaceuticals Ltd.	6,7-oxygenated steroids and uses related thereto
CN1131237C (zh) *	1997-09-26	2003-12-17	中国人民解放军军事医学科学院放射医学研究所	甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
ATE337788T1 (de) *	1998-03-26	2006-09-15	Phytopharm Plc	Steroidale saponine zur behandlung der alzheimerischen krankheit
GB9923076D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
GB9923078D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
GB9923077D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
GB0000228D0 (en) *	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
JP2002030096A (ja) *	2000-07-11	2002-01-29	Kyorin Pharmaceut Co Ltd	神経細胞突起再生剤及びその製造方法
CA2479249A1 (en) *	2002-03-15	2003-09-25	Samaritan Pharmaceuticals, Inc.	Neuroprotective spirostenol pharmaceutical compositions

2003
- 2003-03-27 PL PL372941A patent/PL213697B1/pl not_active IP Right Cessation
- 2003-03-27 WO PCT/GB2003/001380 patent/WO2003082893A2/en not_active Ceased
- 2003-03-27 NZ NZ547897A patent/NZ547897A/en unknown
- 2003-03-27 PE PE2003000315A patent/PE20040306A1/es not_active Application Discontinuation
- 2003-03-27 IL IL16416103A patent/IL164161A0/xx unknown
- 2003-03-27 TW TW092106926A patent/TWI329016B/zh not_active IP Right Cessation
- 2003-03-27 AT AT03722713T patent/ATE424211T1/de active
- 2003-03-27 RU RU2004130281/15A patent/RU2332999C2/ru not_active IP Right Cessation
- 2003-03-27 CN CN038071886A patent/CN1642558B/zh not_active Expired - Fee Related
- 2003-03-27 NZ NZ547344A patent/NZ547344A/en unknown
- 2003-03-27 KR KR1020107017081A patent/KR20100093621A/ko not_active Abandoned

Also Published As

Publication number	Publication date
IL164161A0 (en)	2005-12-18
WO2003082893A2 (en)	2003-10-09
KR20100093621A (ko)	2010-08-25
PE20040306A1 (es)	2004-05-29
ATE424211T1 (de)	2009-03-15
CN1642558B (zh)	2012-05-30
RU2004130281A (ru)	2006-01-20
WO2003082893A8 (en)	2003-12-31
NZ547897A (en)	2008-02-29
PL213697B1 (pl)	2013-04-30
RU2332999C2 (ru)	2008-09-10
CN1642558A (zh)	2005-07-20
TWI329016B (en)	2010-08-21
WO2003082893A3 (en)	2004-04-15
NZ547344A (en)	2007-11-30
TW200400042A (en)	2004-01-01

Legal Events

Date	Code	Title	Description
2014-04-30	LAPS	Decisions on the lapse of the protection rights	Effective date: 20130327

Publication	Publication Date	Title
IL164161A0 (en)	2005-12-18	Therapeutic methods and uses of sapogenins and their derivatives
WO2002079221A3 (en)	2003-04-17	Sapogenin derivatives, their synthesis and use
PT1246835E (pt)	2009-04-15	Sapogeninas substituídas e sua utilização
GB9923076D0 (en)	1999-12-01	Sapogenin derivatives and their use
PL343508A1 (en)	2001-08-27	Smilagenin and anzurogenin-d and their use
TW200528117A (en)	2005-09-01	Methods and reagents for the treatment of proliferative diseases
WO2003090695A3 (en)	2004-05-06	TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
CA2385410A1 (en)	2001-04-05	Sapogenin derivatives and their use in the treatment of cognitive dysfunction
WO2001079164A3 (en)	2002-05-23	N-substituted dithiocarbamates for the treatment of biological disorders
TW200640944A (en)	2006-12-01	VGF polypeptides and methods of treating VGF-related disorders
GB9923078D0 (en)	1999-12-01	Sapogenin derivatives and their use
WO2005000208A3 (en)	2005-04-21	Combination therapy for the treatment of neoplasms
MXPA02000680A (es)	2002-07-02	Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
HRP20041009A2 (en)	2004-12-31	Theraputic methods and uses of sapogenins and their derivatives
WO2004034889A3 (en)	2004-08-12	Photodynamic therapy for ocular neovascularization
WO2004105696A3 (en)	2005-02-10	Combination therapy for the treatment of neoplasms
IL171384A (en)	2010-12-30	Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
TW200833344A (en)	2008-08-16	Therapeutic methods and uses of sapogenins and their derivatives
WO2005058911A3 (en)	2005-08-25	Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
BR0308788A (pt)	2005-01-11	Processos terapêuticos e usos de sapogeninas e seus derivados
WO2004103985A3 (en)	2005-03-24	Derivatives of fusarochromanone as therapeutic agents
MY134920A (en)	2008-01-31	5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2004073631A3 (en)	2007-11-15	Combination therapy for the treatment of neoplasms
AU2002951831A0 (en)	2002-10-24	Underpants for the treatment of pelvic floor muscles and/or bladder